Treatment with AZA+atRA or AZA+AM80; RNA-seq and ChIP-seq to assess transcriptional and enhancer changes; immunofluorescence and Western blot for NR2F1, p27, SMAD2/3/4; SMAD4 shRNA knockdown for functional validation; CAM and mouse assays to evaluate tumor growth, dormancy, and metastasis suppression. This evidence concerns the gene NR2F1 and neoplasm.